As of 4:14pm ET
| -1.35 / -3.06%|
The 8 analysts offering 12-month price forecasts for Neurocrine Biosciences Inc have a median target of 65.00, with a high estimate of 86.00 and a low estimate of 55.00. The median estimate represents a +52.15% increase from the last price of 42.72.
The current consensus among 9 polled investment analysts is to Buy stock in Neurocrine Biosciences Inc. This rating has held steady since September, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.